tbuckley/cabot-search huggingface dataset:
ATIM-14. FIRST KOREAN EXPERIENCE OF DENDRITE CELL-BASED IMMUNOTHERAPY IN PATIENTS WITH PRIMARY GLIOBLASTOMA
Authors: Jaejoon Lim, Kyung gi Cho
Journal: Neuro-Oncology (2016)

Dendritic cells are antigen presenting cells that recognize antigens and trigger an immune response in human immune system. Dendrite cell-based immunotherapy (DCI) has the potential to target and eliminate GBM cells. We evaluated the safety and efficacy of DCI in patients with primary glioblastoma. The dendritic cells sensitized with self-tumor lysate, WT1 and KLH are intradermal injected on upper arm. We administrated the dendritic cells four times every two weeks and twice at intervals of two weeks after the 4weeks of rest period. We followed up patients two years. Treatment response was evaluated with CT and MRI, and immune response was evaluated with T cell proliferation assay and ELISPOT test. The Control group was set up to histological reference (newly diagnosed, standard treatment completed 24 patients). Thirteen patients received this immunotherapy. The total 83 related adverse events occurred. The eighty-two (Grade I) and one (Grade II) reactions were not serious adverse effects. Immune response (antigen specific IFN-γ and T-cell proliferation) was confirmed. The median progression free survival (PFS) was 15.6 months and the median overall survival (OS) was 28.4 months. DCI led to an extension of PFS (8.2 months; wilcoxon p = 0.084) and OS (16.1 months; wilcoxon p = 0.029) compared to control group. In IDH-1 non-mutation with gross total resection patients group, DCI showed 27 months of survival advantage (wilcoxon p = 0.019) compared to control group. Dendritic cell-based Immunotherapy in patients with primary glioblastoma is comparative safe and had minor adverse reactions. DCI results in a longer PFS and OS compared to histological reference and well-tolerated. DCI is a good complementary treatment for primary glioblastoma.
Genome-Wide Convergence during Evolution of Mangroves from Woody Plants
Authors: Shaohua Xu, Ziwen He, Zixiao Guo, Zhang Zhang, Gerald J. Wyckoff, Anthony Greenberg, Chung-I Wu, Suhua Shi
Journal: Molecular Biology and Evolution (2017)

When living organisms independently invade a new environment, the evolution of similar phenotypic traits is often observed. An interesting but contentious issue is whether the underlying molecular biology also converges in the new habitat. Independent invasions of tropical intertidal zones by woody plants, collectively referred to as mangrove trees, represent some dramatic examples. The high salinity, hypoxia, and other stressors in the new habitat might have affected both genomic features and protein structures. Here, we developed a new method for detecting convergence at conservative Sites (CCS) and applied it to the genomic sequences of mangroves. In simulations, the CCS method drastically reduces random convergence at rapidly evolving sites as well as falsely inferred convergence caused by the misinferences of the ancestral character. In mangrove genomes, we estimated ∼400 genes that have experienced convergence over the background level of convergence in the nonmangrove relatives. The convergent genes are enriched in pathways related to stress response and embryo development, which could be important for mangroves' adaptation to the new habitat.
Sequential Quantitative Minimal Residual Disease in BCR-ABL Positive Acute Lymphoblastic Leukaemia: Differential Observations between Major and Minor Fusion Gene Rearrangements and Variation Due to Source Material.
Authors: Gareth Gerrard, Wayne Mitchell, Anthony Goldstone, Raj Chopra, Georgina Buck, Sue Richards, Letizia Foroni
Journal: Blood (2004)
Very Good Response and Overall Survival after Allogeneic Stem Cell Transplantation in Patients with Systemic Light Chain Amyloidosis; Results of a Non-Interventional Study By the Plasma Cell Disorder Subcommittee of the Chronic Malignancy Working Party of the EBMT
Authors: Stefan Schönland, Ute Hegenbart, Simona Iacobelli, Jennifer Hoek, Jakob R. Passweg, Dominique Bordessoule, Jean-Henri Bourhis, Martin R. Schipperus, Theo deWitte, Laurent Garderet, Nicolaus Kröger
Journal: Blood (2015)
Defective ATG16L1-mediated removal of IRE1α drives Crohn’s disease–like ileitis
Authors: Markus Tschurtschenthaler, Timon E. Adolph, Jonathan W. Ashcroft, Lukas Niederreiter, Richa Bharti, Svetlana Saveljeva, Joya Bhattacharyya, Magdalena B. Flak, David Q. Shih, Gwenny M. Fuhler, Miles Parkes, Kenji Kohno, Takao Iwawaki, C. Janneke van der Woude, Heather P. Harding, Andrew M. Smith, Maikel P. Peppelenbosch, Stephan R. Targan, David Ron, Philip Rosenstiel, Richard S. Blumberg, Arthur Kaser
Journal: The Journal of Experimental Medicine (2017)

ATG16L1T300A, a major risk polymorphism in Crohn's disease (CD), causes impaired autophagy, but it has remained unclear how this predisposes to CD. In this study, we report that mice with Atg16l1 deletion in intestinal epithelial cells (IECs) spontaneously develop transmural ileitis phenocopying ileal CD in an age-dependent manner, driven by the endoplasmic reticulum (ER) stress sensor IRE1α. IRE1α accumulates in Paneth cells of Atg16l1ΔIEC mice, and humans homozygous for ATG16L1T300A exhibit a corresponding increase of IRE1α in intestinal epithelial crypts. In contrast to a protective role of the IRE1β isoform, hyperactivated IRE1α also drives a similar ileitis developing earlier in life in Atg16l1;Xbp1ΔIEC mice, in which ER stress is induced by deletion of the unfolded protein response transcription factor XBP1. The selective autophagy receptor optineurin interacts with IRE1α, and optineurin deficiency amplifies IRE1α levels during ER stress. Furthermore, although dysbiosis of the ileal microbiota is present in Atg16l1;Xbp1ΔIEC mice as predicted from impaired Paneth cell antimicrobial function, such structural alteration of the microbiota does not trigger ileitis but, rather, aggravates dextran sodium sulfate-induced colitis. Hence, we conclude that defective autophagy in IECs may predispose to CD ileitis via impaired clearance of IRE1α aggregates during ER stress at this site.
Comparative Functional Genomic Analysis of Myelodysplasia (MDS) in Fanconi Anemia (FA).
Authors: Grover C. Bagby, Shannon McWeeney, Jane Yates, Byung Park, R. Keaney Rathbun, Daniela Pilonetto, Richard Harris, John Wagner, Christina Harrington, Motomi Mori, Ricardo Pasquini, D. Wade Clapp
Journal: Blood (2006)
Detection of Highly Clonal CD34+, Mononuclear Bone Marrow and Peripheral Blood Cells From Patients with Myelodysplastic Syndrome and Age Related Increase of Clonal Hematopoiesis In Healthy Subjects Using a Novel Transcriptional Pyrosequencing Based Clonality Assay
Authors: Maximilian Mossner, Daniel Nowak, Marion Klaumünzer, Verena Nowak, Katrin Ackermann, Susanne Brendel, Julia Obländer, Olaf Hopfer, Claudia Baldus, Eckhard Thiel, Wolf-Karsten Hofmann
Journal: Blood (2010)
501O_PR Epidemiology, real world treatment and outcomes of 423 patients (pts) with angiosarcoma (AS) in Asia: A report from the Asian Sarcoma Consortium (ASC)
Authors: R. Quek, H.H. Loong, V. Sriuranpong, M. Farid, S.H. Tan, W.L. Goh, S. Mingmalairak, T.W-W. Chen, C-C. Chang, A. Pang, S. Teo, M.E. Puhaindran, M.M. Maw, R. Ngan, A.K.C. Leung, J.C. Chan, T. Hirose, M. Endo, A. Kawai
Journal: Annals of Oncology (2016)
MLN4924, an Investigational Small Molecule Inhibitor of NEDD8-Activating Enzyme (NAE), Inhibits NF-κB Activity and Induces G1 Cell Cycle Arrest and Apoptosis in Pre-Clinical Models of Hodgkin Lymphoma (HL)
Authors: Matthew J. Barth, Cory Mavis, Francisco J. Hernandez-Ilizaliturri, Myron S. Czuczman
Journal: Blood (2012)
RhIg-prophylaxis is not influenced by FCGR2/3 polymorphisms involved in red blood cell clearance
Authors: Tamara C. Stegmann, Barbera Veldhuisen, Sietse Q. Nagelkerke, Dian Winkelhorst, Henk Schonewille, Esther P. Verduin, Taco W. Kuijpers, Masja de Haas, Gestur Vidarsson, C. Ellen van der Schoot
Journal: Blood (2017)
Evaluation of effects of aging, training and myocardial ischemia on cardiac reserve by exercise echocardiography.
Authors: Yasuki Mizutani, Sagami Nakano, Nobuyuki Ote, Takanori Iwase, Takao FUJlNAMI
Journal: Circulation (1984)

Exercise tolerance and heart response were examined by cross-sectional echocardiography before and during exercise tests to assess the effects of aging, training and myocardial ischemia on the cardiac reserve of 40 healthy men, 20 athletes and 25 patients with angina on effort. The cardiac response to exercise can be divided into 4 types according to parameters derived from a short axis section echocardiogram. Type A: The left ventricular end-diastolic volume (LVEDV) increased slightly in the early stage of exercise, and thereafter, the cardiac response was maintained by a gradual increase of myocardial contractility and heart rate. Type B: Initial response to exercise was similar to Type A, but cardiac output was maintained only by an increase of heart rate under additional exercise load. Type C: LVEDV, LVESV (left ventricular end-systolic volume) and contractility remained virtually unchanged throughout the exercise. Type D: The contractility decreased from the early stage of the exercise, and LVEDV and LVESV increased. Most young subjects and all athletes showed Type A response, while in the aged healthy subjects the Type B response was more frequent. Anginal cases tolerating 125-watt load responded as Type B or C, and those tolerating only 75 watts showed Type C or D. All patients in Type D had multi-vessel disease.
The Causes and Prevention of Maternal Mortality.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Enhancement of the Antigen-Presenting Cell Function of Mantle Cell Lymphomas (MCL) by Novel Molecularly Based Immunotherapeutic Strategies.
Authors: Hongwei Wang, Fengdong Cheng, D. Noyes, K. Wright, S. Mohapatra, J. Tao, M. Schell, S. Sebti, M. Smith, K. Bhalla, J. Pinilla, S. Dessureault, D. Celis, E.M. Sotomayor
Journal: Blood (2007)
Erythropoiesis Is Highly Stimulated in CD34+ Cells in Low-Risk Myelodysplastic Syndromes (MDS) with an Improper Mitochondrial Function.
Authors: Ramin Tehranchi, Rosangela Invernizzi, Boris Zhivotovsky, Bengt Fadeel, Ann-Mari Forsblom, Erica Travaglino, Jan Samuelsson, Robert Hast, Lars Nilsson, Rolf Wibom, Alf Grandien, Mario Cazzola, Eva Hellstrom-Lindberg
Journal: Blood (2004)
LOW SPARC EXPRESSION IN CML and ITS Upregulation DURING Imatinib TREATMENT.
Authors: Giuseppe Alberto Palumbo, Cesarina Giallongo, Piera La Cava, Daniele Tibullo, Fabio Stagno, Alessandra Romano, Concetta Conticello, Annalisa Chiarenza, Francesco Di Raimondo
Journal: Blood (2009)
Prediction of the Lenalidomide Toxicity and Its Therapeutic Efficacy in Japanese Multiple Myeloma Patients By Measuring Its Plasma Concentration.
Authors: Yoko Kado, Fumiaki Kitazawa, Masayuki Tsujimoto, Shin-ichi Fuchida, Akira Okano, Mayumi Hatsuse, Satoshi Murakami, Kumi Ueda, Takatoshi Kokufu, Shoichi Ozawa, Natsuko Ito, Satoe Morishita, Tetsuya Takada, Tetsuya Minegaki, Kohshi Nishiguchi, Eishi Ashihara, Chihiro Shimazaki
Journal: Blood (2015)
Relation between resting amygdalar activity and cardiovascular events: a longitudinal and cohort study
Authors: Ahmed Tawakol, Amorina Ishai, Richard AP Takx, Amparo L Figueroa, Abdelrahman Ali, Yannick Kaiser, Quynh A Truong, Chloe JE Solomon, Claudia Calcagno, Venkatesh Mani, Cheuk Y Tang, Willem JM Mulder, James W Murrough, Udo Hoffmann, Matthias Nahrendorf, Lisa M Shin, Zahi A Fayad, Roger K Pitman
Journal: The Lancet (2017)
Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study
Authors: Rachid Baz, Thomas G. Martin, Melissa Alsina, Kenneth H. Shain, Hearn J. Cho, Jeffrey L Wolf, Anuj Mahindra, Ajai Chari, Daniel M Sullivan, Lisa A Nardelli, Kenneth Lau, Xiuhua Zhao, Hui-Yi Lin, Sundar Jagannath
Journal: Blood (2014)
Overcoming Chemotherapy Resistance in Childhood Acute Lymphoblastic Leukemia by Targeting Ion Channels.
Authors: Serena Pillozzi, Marika Masselli, Emanuele De Lorenzo, Emanuele Cilia, Olivia Crociani, Amedeo Amedei, Benedetta Accordi, Marinella Veltroni, Giuseppe Basso, Dario Campana, Andrea Becchetti, Annarosa Arcangeli
Journal: Blood (2009)
Low Blood Counts of Memory/Effector CD8 T Cells, Gamma/Delta T Cells, Memory B Cells and Plasmacytoid Dendritic Cells and High Counts of Th2 Cells in Systemic Sclerosis
Authors: Jan Storek, Rob Woolson, Paul K. Wallace, Gregory Sempowski, Peter A. McSweeney, Maureen Mayes, Leslie Crofford, Sharon LeClercq, Richard A. Nash, Keith M. Sullivan
Journal: Blood (2011)
18F-FDG PET/CT Versus Contrast-Enhanced CT for Staging and Prognostic Prediction in Patients With Salivary Gland Carcinomas
Authors: Marn Joon Park, Jungsu S. Oh, Jong-Lyel Roh, Jae Seung Kim, Jeong Hyun Lee, Soon Yuhl Nam, Sang Yoon Kim
Journal: Clinical Nuclear Medicine (2017)

Salivary gland carcinoma (SGC) is rare tumor with various histological type and metastatic potential. Pretreatment detection of metastases can contribute to planning the appropriate treatment of SGC. Therefore, the present study evaluated the utility of F-FDG PET/CT versus contrast-enhanced CT for detection of metastases and prediction of outcomes in SGC patients.Sixty-seven consecutive SGC patients who were prospectively evaluated by F-FDG PET/CT and contrast-enhanced CT and subsequently underwent surgery with or without postoperative radiotherapy/chemoradiotherapy were included. The diagnostic values of both imaging modalities for detection of metastatic diseases were compared with McNemar test and logistic regression using generalized estimating equations. Cox proportional hazard modeling was used to assess the prognostic values of the quantitative metabolic measurements detected by F-FDG PET/CT and of other clinical factors.Among 67 SGC patients, 17 (25.4%) had cervical metastasis, and 4 (6%) had distant metastasis at initial staging. The sensitivity of F-FDG PET/CT for detection of cervical metastasis was significantly higher than those of CT (P < 0.05), and those of F-FDG PET/CT and CT for detection of distant metastasis did not differ (P > 0.5). Regional and distant site metastases were most reliably predicted by high-grade pathological analysis (P < 0.05). Extranodal extension and metabolic tumor volume measured by F-FDG PET/CT were independent predictors of progression-free survival and overall survival (all P < 0.05).In SGC patients, F-FDG PET/CT detected metastatic diseases with high sensitivity and specificity, and metabolic tumor volumes helped to predict survival outcomes.
An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study
Authors: Ian W. Flinn, Richard H. Van der Jagt, Brad S. Kahl, Peter Wood, Tim E. Hawkins, David MacDonald, Mark Hertzberg, Yiu-Lam Kwan, David Simpson, Michael Craig, Kathryn Kolibaba, Samar Issa, Mihaela C. Munteanu, Regina Clementi, Ling Chen, John M. Burke
Journal: Blood (2012)
A Novel Assay for Development of Chromosomal Lesions in Human CD34+ Cells Following Exposure to Ionizing Radiation Reveals Increased Susceptibility To Acquire Unstable Chromosomal Lesions in CML CD34+ Cells.
Authors: Sujata Chakraborty, Arjun Sehgal, Stephen Forman, Smita Bhatia, Ravi Bhatia
Journal: Blood (2007)
Pharmacokinetics and in vivo stability of intraperitoneally administered therapeutic antibody catumaxomab
Authors: P. Ruf, M. Jäger, C. Volovat, A. Burges, M. M. Heiss, P. Wimberger, B. Brandt, H. Lindhofer
Journal: Journal of Clinical Oncology (2008)

14006 Background: The EpCAM-specific trifunctional rat/mouse hybrid antibody catumaxomab simultaneously activates T cells and Fcγ-receptor positive immune cells redirecting them against the tumor. In a phase II/III randomized study catumaxomab significantly prolonged puncture free survival and time to progression in cancer patients (pts) with symptomatic ascites. Here, the results of the corresponding pharmacokinetic trial are presented. Methods: The pharmacokinetics of catumaxomab were evaluated in a phase II, open- label, multi-centre study in 13 pts with malignant ascites requiring paracentesis. Four intraperitoneal (i.p.) infusions of 10, 20, 50 and 150 μg catumaxomab were administered within 11 days. Antibody concentrations were quantified by a high-sensitivity ELISA in ascites and plasma to determine local and systemic exposure. Immunological activity of catumaxomab was measured using a potency assay. Anti-drug antibody (ADA) development was monitored applying a bridging ELISA. Results: 10 pts receiving all four infusions were evaluable. Increasing concentrations (C) of free catumaxomab were detected in ascites fluid during the course of the treatment. Median Cascites before the last infusion was 6121 pg/ml. Systemic exposure was observed in 9 pts with median Cmax of 403 pg/ml. High inter-individual variability was demonstrated by Area Under the Curve AUC0-tlast values ranging between 0 and 10,020 day*pg/ml (median = 2,045). There was no correlation between safety parameters and systemic C. Elimination half life t1/2 was 2.13 days in mean. The therapeutic antibody exhibited remarkable in vivo stability remaining almost fully immunologically active (80–100%) even after three days of circulation in ascites. Also systemic catumaxomab in plasma still revealed 50–60% bioactivity. None of the pts developed significant ADA responses (> 100 ng/ml) until the time of last infusion. Conclusions: The relatively long t1/2 of 2.13 days and the high in vivo stability of immunologically active catumaxomab support its observed clinical efficacy. High local C, minor systemic exposure with an acceptable safety profile and ADA onset not until the last i.p. infusion confirm the appropriateness of the chosen dosing scheme. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Fresenius Biotech, Trion Pharma, Trion Research Trion Pharma, Trion Research
Multiparameter Flow Cytometry Analysis of Peripheral Blood T, NK and Dendritic Cells From High-Risk Smoldering Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone
Authors: Bruno Paiva, Lucía López-Corral, María-Belén Vidriales, Luis Ignacio Sánchez Abarca, Miguel T. Hernandez, Joan Bargay, Javier De La Rubia, Pilar Giraldo, Ana-Isabel Teruel, Laura Rosiñol, Albert Oriol, Jose Hernández, Felipe de Arriba, Graça Esteves, Jose Antonio Pérez Simón, María-Victoria Mateos, Jesus F San Miguel
Journal: Blood (2010)
miR-4775 promotes colorectal cancer invasion and metastasis via the Smad7/TGFβ-mediated epithelial to mesenchymal transition
Authors: Senlin Zhao, Hongcheng Sun, Weiliang Jiang, Yushuai Mi, Dongyuan Zhang, Yugang Wen, Dantong Cheng, Huamei Tang, Shaohan Wu, Yang Yu, Xisheng Liu, Weiyingqi Cui, Meng Zhang, Xiaofeng Sun, Zongguang Zhou, Zhihai Peng, Dongwang Yan
Journal: Molecular Cancer (2017)

Despite advancements in the diagnosis and treatment of colorectal cancer (CRC), many patients die because of tumor metastasis or recurrence. Therefore, identifying new prognostic markers and elucidating the mechanisms of CRC metastasis and recurrence will help to improve the prognosis of the disease. As dysregulation of microRNAs is strongly related to cancer progression, the aim of this study was to identify the role of miR-4775 in the prognosis of CRC patients and the underling mechanisms involved in CRC progression. qPCR and in situ hybridization were used to evaluate the expression of miR-4775 in 544 pairs of paraffin-embedded normal and CRC tissues. Kaplan–Meier analysis with the log-rank test was used for survival analyses. Immunohistochemical staining was applied to investigate the expression of miR-4775-regulated Smad7/TGFβ pathway-associated markers. In vitro and in vivo invasion and metastasis assays were used to explore the function of miR-4775 in the progression of CRC. miR-4775 was identified as a high-risk factor for CRC metastasis and recurrence, with high levels predicting poor survival among the 544 studied CRC patients. Furthermore, high miR-4775 expression promoted the invasion of CRC cells as well as metastasis and the epithelial to mesenchymal transition (EMT) via Smad7-mediated activation of TGFβ signaling both in vitro and in vivo. Downregulating miR-4775 or overexpressing Smad7 reversed the tumor-promoting roles of miR-4775/Smad7/TGFβ in vitro and in vivo. miR-4775 promotes CRC metastasis and recurrence in a Smad7/TGFβ signaling-dependent manner, providing a new therapeutic target for inhibiting the metastasis or recurrence of the disease.
RNAi Screening Identifies BCL-XL As An Erythroid Lineage-Specific 5-Azacytidine Sensitizer While the BCL-2/BCL-XL/BCL-W Inhibitor ABT-737 Results in More Universal Sensitization in Leukemia Cells,
Authors: James M Bogenberger, Chang-Xin Shi, Irma Gonzales, Rodger E. Tiedemann, Pierre Noel, James L. Slack, Ruben A. Mesa, Keith Stewart, Yihua Qiu, Kevin R Coombes, Steven M. Kornblau, David Azorsa, Raoul Tibes
Journal: Blood (2011)
Rituximab (R) Maintenance Versus Observation After Short Term Chemoimmunotherapy R-FND as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Updated Results and Safety of the Maintenance of An Intergruppo Italiano Linfomi (IIL) Randomized Trial.
Authors: Umberto Vitolo, Carola Boccomini, Marco Ladetto, Enrica Gamba, Isabel Alvarez, Luca Baldini, Annalisa Chiappella, Annalisa Chiarenza, Paolo Corradini, Amalia De Renzo, Andrea Evangelista, Andrea Gallamini, Attilio Guarini, Stefan Hohaus, Anna Marina Liberati, Barbara Mantoan, Lorella Orsucci, Guido Parvis, Mario Petrini, Antonello Pinto, Enrico Pogliani, Samantha Pozzi, Alessandro Pulsoni, Luigi Rigacci, Eleonora Russo, Corrado Tarella, Alessandra Tucci, Francesco Zaja, Eugenio Gallo
Journal: Blood (2009)
Expression of SOCS1 and SOCS3 Genes with Human Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Tae Hyang Lee, Ji Yoon Lee, Sohye Park, Jae-Ho Yoon, Seung Hwan Shin, Byung-Sik Cho, Dong-Gun Lee, Woo-Sung Min, Heeje Kim
Journal: Blood (2012)